A comparison of QuantStudio™ 3D Digital PCR and ARMS-PCR for measuring plasma EGFR T790M mutations of NSCLC patients

References

• ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin201666211513226808342
   PubMed Web of Science ®Google Scholar
• HongQYWuGMQianGSPrevention and management of lung cancer in ChinaCancer2015121Suppl 173080308826331814
   PubMed Web of Science ®Google Scholar
• ReckMPopatSReinmuthNDe RuysscherDKerrKMPetersSESMO Guidelines Working GroupMetastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201425Suppl 3iii27iii3925115305
   PubMed Web of Science ®Google Scholar
• ChenZFillmoreCMHammermanPSKimCFWongKKNon-small-cell lung cancers: a heterogeneous set of diseasesNat Rev Cancer201414853554625056707
   PubMed Web of Science ®Google Scholar
• SharmaSVBellDWSettlemanJHaberDAEpidermal growth factor receptor mutations in lung cancerNat Rev Cancer20077316918117318210
   PubMed Web of Science ®Google Scholar
• TanCSGilliganDPaceySTreatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancerLancet Oncol2015169e44745926370354
   PubMed Web of Science ®Google Scholar
• TanDSMokTSRebbeckTRCancer genomics: diversity and disparity across ethnicity and geographyJ Clin Oncol20163419110126578615
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• KimESHirshVMokTGefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialLancet200837296521809181819027483
   PubMed Web of Science ®Google Scholar
• SequistLVYangJCYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273327333423816960
   PubMed Web of Science ®Google Scholar
• WuYLZhouCHuCPAfatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialLancet Oncol201415221322224439929
   PubMed Web of Science ®Google Scholar
• ShiYZhangLLiuXIcotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trialLancet Oncol2013141095396123948351
   PubMed Web of Science ®Google Scholar
• OhashiKMaruvkaYEMichorFPaoWEpidermal growth factor receptor tyrosine kinase inhibitor-resistant diseaseJ Clin Oncol20133181070108023401451
   PubMed Web of Science ®Google Scholar
• YunCHMengwasserKETomsAVThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProc Natl Acad Sci U S A200810562070207518227510
   PubMed Web of Science ®Google Scholar
• YuHAArcilaMERekhtmanNAnalysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancersClin Cancer Res20131982240224723470965
   PubMed Web of Science ®Google Scholar
• LinYWangXJinHEGFR-TKI resistance in NSCLC patients: mechanisms and strategiesAm J Cancer Res20144541143525232485
   PubMed Web of Science ®Google Scholar
• ChongCRJännePAThe quest to overcome resistance to EGFR-targeted therapies in cancerNat Med201319111389140024202392
   PubMed Web of Science ®Google Scholar
• XuXMaoLXuWAC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance in animal models and lung cancer patientsMol Cancer Ther201615112586259727573423
   PubMed Web of Science ®Google Scholar
• KimESOlmutinib: first global approvalDrugs201676111153115727357069
   PubMed Web of Science ®Google Scholar
• SequistLVSoriaJCGadgeelSMFirst-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)J Clin Oncol20143215 Suppl8010
   Web of Science ®Google Scholar
• GreigSLOsimertinib: first global approvalDrugs201676226327326729184
   PubMed Web of Science ®Google Scholar
• MokTSWuYLAhnMJOsimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancerN Engl J Med2017376762964027959700
   PubMed Web of Science ®Google Scholar
• ChabonJJSimmonsADLovejoyAFCirculating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patientsNat Commun201671181527283993
   PubMed Web of Science ®Google Scholar
• BettegowdaCSausenMLearyRJDetection of circulating tumor DNA in early- and late-stage human malignanciesSci Transl Med20146224224ra24
   PubMed Web of Science ®Google Scholar
• MisaleSYaegerRHoborSEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerNature2012486740453253622722830
   PubMed Web of Science ®Google Scholar
• DiazLAJrWilliamsRTWuJThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancersNature2012486740453754022722843
   PubMed Web of Science ®Google Scholar
• CrowleyEDi NicolantonioFLoupakisFBardelliALiquid biopsy: monitoring cancer-genetics in the bloodNat Rev Clin Oncol201310847248423836314
   PubMed Web of Science ®Google Scholar
• DiehlFSchmidtKChotiMACirculating mutant DNA to assess tumor dynamicsNat Med200814998599018670422
   PubMed Web of Science ®Google Scholar
• HoldhoffMSchmidtKDonehowerRDiazLAJrAnalysis of circulating tumor DNA to confirm somatic KRAS mutationsJ Natl Cancer Inst2009101181284128519641175
   PubMed Web of Science ®Google Scholar
• XuTKangXYouXCross-platform comparison of four leading technologies for detecting EGFR mutations in circulating tumor DNA from non-small cell lung carcinoma patient plasmaTheranostics2017761437144628529628
   PubMed Web of Science ®Google Scholar
• ThressKSBrantRCarrTHEGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291Lung Cancer201590350951526494259
   PubMed Web of Science ®Google Scholar
• OxnardGRThressKSAldenRSAssociation between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancerJ Clin Oncol201634283375338227354477
   PubMed Web of Science ®Google Scholar
• GuJZangWLiuBP2.03b-098 comparison of digital PCR, ion proton with ARMS-PCR in tumor tissue and plasma of NSCLC patients2017121S996
   Google Scholar
• YaoYLiuJLiLDetection of circulating tumor DNA in patients with advanced non-small cell lung cancerOncotarget2017822130214027791985
   PubMed Web of Science ®Google Scholar
• SequistLVWaltmanBADias-SantagataDGenotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsSci Transl Med201137575ra26
   PubMed Web of Science ®Google Scholar
• SorensenBSWuLWeiWMonitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinibCancer2014120243896390125103305
   PubMed Web of Science ®Google Scholar
• IchiharaELovlyCMShades of T790M: intratumor heterogeneity in EGFR-mutant lung cancerCancer Discov20155769469626152920
   PubMed Web of Science ®Google Scholar
• KarlovichCGoldmanJWSunJMAssessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a Phase I study of rociletinib (CO-1686)Clin Cancer Res201622102386239526747242
   PubMed Web of Science ®Google Scholar
• KeEEWuYLEGFR as a pharmacological target in EGFR-mutant non-small-cell lung cancer: where do we stand nowTrends Pharmacol Sci2016371188790327717507
   PubMed Web of Science ®Google Scholar
• ConteDVerriCBorziCNovel method to detect microRNAs using chip-based QuantStudio 3D digital PCRBMC Genomics20151684926493562
   PubMed Web of Science ®Google Scholar
• PaoWMillerVAPolitiKAAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainPLoS Med200523e7315737014
   PubMed Web of Science ®Google Scholar
• KobayashiSBoggonTJDayaramTEGFR mutation and resistance of non-small-cell lung cancer to gefitinibN Engl J Med2005352878679215728811
   PubMed Web of Science ®Google Scholar
• IshiiHAzumaKSakaiKDigital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: correlation with paired tumor samplesOncotarget2015631308503085826334838
   PubMed Web of Science ®Google Scholar
• ZhengDYeXZhangMZPlasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistanceSci Rep201662091326867973
   PubMed Web of Science ®Google Scholar